SMARCA5 and prostate carcinoma: Moreover, USP3 knockdown sensitizes cancer cells to DNA-damaging agents in xenograft models, suggesting that the USP3- SMARCA5 axis may provide new therapeutic targets for overcoming chemotherapy resistance in prostate cancer.